American Association for Cancer Research
Browse
00085472can143516-sup-141739_1_supp_2841435_n6xg6n_eps_zip.zip (4.2 MB)

Supplementary Figure S1 from Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR–Ligand Off-Rates Measurements on Living Cells

Download (4.2 MB)
software
posted on 2023-03-30, 23:12 authored by Michael Hebeisen, Julien Schmidt, Philippe Guillaume, Petra Baumgaertner, Daniel E. Speiser, Immanuel Luescher, Nathalie Rufer

Supplementary Figure S1. Determination of TCR-ligand off-rates on a panel of CD8+ T cells engineered with TCRs of incremental affinities against the A2/NY-ESO-1 tumor antigen.

History

ARTICLE ABSTRACT

The avidity of the T-cell receptor (TCR) for antigenic peptides presented by the peptide–MHC (pMHC) on cells is a key parameter for cell-mediated immunity. Yet a fundamental feature of most tumor antigen-specific CD8+ T cells is that this avidity is low. In this study, we addressed the need to identify and select tumor-specific CD8+ T cells of highest avidity, which are of the greatest interest for adoptive cell therapy in patients with cancer. To identify these rare cells, we developed a peptide–MHC multimer technology, which uses reversible Ni2+-nitrilotriacetic acid histidine tags (NTAmers). NTAmers are highly stable but upon imidazole addition, they decay rapidly to pMHC monomers, allowing flow-cytometric–based measurements of monomeric TCR–pMHC dissociation rates of living CD8+ T cells on a wide avidity spectrum. We documented strong correlations between NTAmer kinetic results and those obtained by surface plasmon resonance. Using NTAmers that were deficient for CD8 binding to pMHC, we found that CD8 itself stabilized the TCR–pMHC complex, prolonging the dissociation half-life several fold. Notably, our NTAmer technology accurately predicted the function of large panels of tumor-specific T cells that were isolated prospectively from patients with cancer. Overall, our results demonstrated that NTAmers are effective tools to isolate rare high-avidity cytotoxic T cells from patients for use in adoptive therapies for cancer treatment. Cancer Res; 75(10); 1983–91. ©2015 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC